Minerva Neurosciences, Inc. (NERV)Healthcare | Biotechnology | Burlington, United States | NasdaqCM
2.35 USD
-0.17
(-6.561%) ⇩
(Oct. 14, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 1:39 a.m. EDT
Minerva Neurosciences presents a catastrophic long-term investment case defined by a decade-long structural decline. The price has eroded nearly 98% over the last nine years, with seven consecutive years of negative annual returns ending in another drop. This relentless downward trajectory, combined with negative book value, negative free cash flow, and negative earnings, indicates a business that the market has consistently reassessed as failing to generate value. While a $200 million financing deal and positive news headlines offer temporary relief, they cannot reverse the fundamental deterioration evidenced by the multi-year price collapse. The balance sheet is fragile, and the company is burning cash without sustainable profitability. For investors, this is a clear 'avoid' signal; the market has already priced in the failure of the current business model, and the odds of a rapid, fundamental reversal are low given the severity of the decline. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.090290 |
| AutoETS | 0.097280 |
| AutoARIMA | 0.097280 |
| MSTL | 0.098861 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 35% |
| H-stat | 2.96 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.620 |
| Excess Kurtosis | -0.64 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Market Cap | 112,206,760 |
| Forward P/E | -5.60 |
| Beta | -0.12 |
| Website | https://www.minervaneurosciences.com |
As of Oct. 10, 2026, 1:39 a.m. EDT: Options activity is extremely sparse with negligible open interest and volume across all expirations. The lack of meaningful positioning suggests a lack of speculative conviction in either direction, reflecting the stock's illiquid status and the absence of a clear catalyst driving immediate price discovery.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.0019919872 |
| Address1 | 1,500 District Avenue |
| All Time High | 126.72 |
| All Time Low | 1.15 |
| Ask | 3.23 |
| Ask Size | 2 |
| Audit Risk | 7 |
| Average Daily Volume10 Day | 111,590 |
| Average Daily Volume3 Month | 182,009 |
| Average Volume | 182,009 |
| Average Volume10Days | 111,590 |
| Beta | -0.118 |
| Bid | 2.09 |
| Bid Size | 2 |
| Board Risk | 9 |
| Book Value | -4.516 |
| City | Burlington |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 7 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 2.35 |
| Current Ratio | 20.144 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 2.565 |
| Day Low | 2.31 |
| Display Name | Minerva Neurosciences |
| Dividend Yield | 0.0 |
| Earnings Timestamp End | 1,754,397,000 |
| Earnings Timestamp Start | 1,754,397,000 |
| Ebitda | -28,534,206 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -3.809 |
| Enterprise Value | 108,680,832 |
| Eps Current Year | -0.57 |
| Eps Forward | -0.42 |
| Eps Trailing Twelve Months | -36.12 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 4.0241 |
| Fifty Day Average Change | -1.6740999 |
| Fifty Day Average Change Percent | -0.4160185 |
| Fifty Two Week Change Percent | 0.19919872 |
| Fifty Two Week High | 12.46 |
| Fifty Two Week High Change | -10.110001 |
| Fifty Two Week High Change Percent | -0.81139654 |
| Fifty Two Week Low | 2.31 |
| Fifty Two Week Low Change | 0.03999996 |
| Fifty Two Week Low Change Percent | 0.017316 |
| Fifty Two Week Range | 2.31 - 12.46 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,404,221,400,000 |
| Float Shares | 34,299,936 |
| Forward Eps | -0.42 |
| Forward P E | -5.595238 |
| Free Cashflow | -8,862,641 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 7 |
| Fullday Change | -0.1650002 |
| Fullday Change Percent | -6.5868335 |
| Fullday Price | 2.35 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.0 |
| Gross Profits | -15,541,195 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.03263 |
| Held Percent Institutions | 0.93319 |
| Implied Shares Outstanding | 47,747,559 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,655,769,600 |
| Last Split Factor | 1:8 |
| Long Business Summary | Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts. |
| Long Name | Minerva Neurosciences, Inc. |
| Market | us_market |
| Market Cap | 112,206,760 |
| Market State | POST |
| Max Age | 86,400 |
| Message Board Id | finmb_261133065 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -394,349,728 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 166,638,980 |
| Number Of Analyst Opinions | 3 |
| Open | 2.51 |
| Operating Cashflow | -26,168,724 |
| Operating Margins | 0.0 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Phone | 617 600 7373 |
| Previous Close | 2.515 |
| Price Eps Current Year | -4.122807 |
| Price Hint | 4 |
| Price To Book | -0.52037203 |
| Profit Margins | 0.0 |
| Quick Ratio | 19.016 |
| Quote Source Name | Delayed Quote |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.1650002 |
| Regular Market Change Percent | -6.5606437 |
| Regular Market Day High | 2.565 |
| Regular Market Day Low | 2.31 |
| Regular Market Day Range | 2.31 - 2.565 |
| Regular Market Open | 2.51 |
| Regular Market Previous Close | 2.515 |
| Regular Market Price | 2.35 |
| Regular Market Time | 1,792,008,000 |
| Regular Market Volume | 254,313 |
| Return On Assets | -0.28424 |
| Sand P52 Week Change | 0.17004645 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 47,747,559 |
| Shares Percent Shares Out | 0.051 |
| Shares Short | 2,435,917 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 2,112,663 |
| Short Name | Minerva Neurosciences, Inc |
| Short Percent Of Float | 0.053400002 |
| Short Ratio | 15.6 |
| Source Interval | 15 |
| State | MA |
| Symbol | NERV |
| Target High Price | 14.0 |
| Target Low Price | 7.0 |
| Target Mean Price | 10.33333 |
| Target Median Price | 10.0 |
| Total Cash | 75,267,248 |
| Total Cash Per Share | 1.576 |
| Total Debt | 60,000,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -36.12 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 5.025525 |
| Two Hundred Day Average Change | -2.6755252 |
| Two Hundred Day Average Change Percent | -0.5323872 |
| Type Disp | Equity |
| Volume | 254,313 |
| Website | https://www.minervaneurosciences.com |
| Zip | 1,803 |